Listed

Humana Inc: Form 10-Q for the period ended Jun 30, 2014

Filed with the SEC on Jul 30, 2014 and accepted by EDGAR at Jul 30, 2014, 17:01 ET.

Share

Management's discussion and analysis

As filed, 79,973 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward–looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2013 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 19, 2014, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward–looking statements.

Executive Overview

General

Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company’s strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.

Business Segments

On January 1, 2014, we reclassified certain of our businesses from our Healthcare Services segment to our Employer Group segment to correspond with internal management reporting changes. Our reportable segments remain the same and prior period segment financial information has been recast to conform to the 2014 presentation.

We manage our business with three reportable segments: Retail, Employer Group, and Healthcare Services. In addition, the Other Businesses category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles. These segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer to assess performance and allocate resources.

The Retail segment consists of Medicare and commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products, marketed directly to individuals, and includes our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible, and Long-Term Support Services benefits, collectively our state-based contracts. The Employer Group segment consists of Medicare and commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and voluntary benefit products, as well as administrative services only, or ASO, products and our health and wellness products primarily marketed to employer groups. The Healthcare Services segment includes services offered to our health plan members as well as to third parties including pharmacy, provider services, home based services, integrated behavioral health services and predictive modeling and informatics services. The Other Businesses category consists of our military services, primarily our TRICARE South Region contract, closed-block of long-term care insurance policies, and our Puerto Rico Medicaid contracts under which coverage was terminated effective September 30, 2013.

The results of each segment are measured by income before income taxes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and behavioral health services, to our Retail and Employer Group customers Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and included with intersegment eliminations.

Seasonality

One of the product offerings of our Retail segment is Medicare stand-alone prescription drug plans, or PDPs, under the Medicare Part D program. These plans provide varying degrees of coverage. Our quarterly Retail segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low-income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

Our Employer Group segment also experiences seasonality in the benefit ratio pattern. However, the effect is opposite of Medicare stand-alone PDP in the Retail segment, with the Employer Group’s benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. Similarly, certain of our fully-insured individual commercial medical products in our Retail segment experience seasonality in the benefit ratio akin to the Employer Group segment; however, we expect our new plans compliant with the Health Care Reform Law to experience less seasonality than our historical individual commercial medical products.

In addition, the Retail segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare and individual health care exchange marketing seasons.

2014 Highlights

Consolidated

  • Our 2014 results reflect the continued implementation of our strategy to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. At June 30, 2014, approximately 659,200 members, or 27.9%, of our individual Medicare Advantage membership were in risk arrangements under our integrated care delivery model, as compared to 561,500 members, or 27.1%, at December 31, 2013 and 541,400 members, or 26.7%, at June 30, 2013.
  • Our results for the three and six months ended June 30, 2014 as compared to the three and six months ended June 30, 2013, were impacted by investments in health care exchanges and new state-based contracts and higher specialty prescription drug costs associated with a new treatment for Hepatitis C, partially offset by membership growth in our Medicare Advantage, Medicare stand-alone PDP, and individual commercial medical offerings. In addition, year-over-year comparisons were also negatively impacted by sequestration which became effective April 1, 2013.
  • Year-over-year comparisons of the operating cost ratio are impacted by fees mandated by the Health Care Reform Law beginning in 2014, including the non-deductible health insurance industry fee. Likewise, year-over-year comparisons of the benefit ratio reflect the inclusion of these mandated fees in the pricing of our products for 2014.
  • Year-over-year comparisons of diluted earnings per common share are favorably impacted by a lower number of shares used to compute diluted earnings per common share reflecting the impact of share repurchases.
  • Our operating cash flow of $471 million for the six months ended June 30, 2014 compared to operating cash flow of $585 million for the six months ended June 30, 2013. Our operating cash flows for 2014 reflect earnings and enrollment activity and the timing of working capital items including the timing of receipts and payments under certain provisions of the Health Care Reform Law that became effective in 2014. For 2014, the effect of the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law are impacting the timing of our operating cash flows, as we expect to build a receivable in 2014 that will be collected in 2015. It is reasonably possible that the receivable could be material to our operating cash flow in 2014. In 2014, we expect our operating cash flows to decline from 2013.
  • We expect our 2014 financing cash flows to be negatively impacted by the timing of payments to and receipts from CMS associated with Medicare Part D reinsurance subsidies for which we do not assume risk. We are experiencing higher specialty prescription drug costs associated with a new treatment for Hepatitis C than were contemplated in our bids which is resulting in higher reinsurance subsidy receivable balances in 2014 that will be settled in 2015 under the terms of our contracts with CMS.
  • In September 2014, we expect to pay the federal government approximately $560 million for the annual health insurance industry fee. This fee is not deductible for tax purposes, which has significantly increased our effective income tax rate in 2014. The health insurance industry fee is further described below under the section titled “Health Care Reform.”
  • During the six months ended June 30, 2014, we repurchased 0.91 million shares in open market transactions for $112 million and paid dividends to stockholders of $86 million.

Retail

  • On April 7, 2014, CMS announced final 2015 Medicare benchmark payment rates and related technical factors impacting the bid benchmark premiums, which we refer to as the Final Rate Notice. We believe the Final Rate Notice together with the impact of payment cuts associated with the Health Care Reform Law, quality bonuses, sunset of the Star quality CMS demonstration in 2015, risk coding modifications, the impact of the health insurance industry fee, and other funding formula changes, indicate 2015 Medicare Advantage funding cuts of approximately 2%. While we believe our senior members’ benefits may be adversely impacted, we believe we can effectively design Medicare Advantage products based upon these levels of rate reduction while continuing to remain competitive compared to both the combination of original Medicare with a supplement policy as well as Medicare Advantage products offered by our competitors. Failure to execute these strategies may result in a material adverse effect on our results of operations, financial position, and cash flows.
  • Automatic across-the-board budget cuts under the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012, known as “sequestration,” commenced in March 2013, including a 2% reduction in Medicare Advantage and Medicare Part D payments beginning April 1, 2013. While we believe we can reduce Medicare Advantage payments to providers under our network provider contracts in connection with sequestration, a number of hospitals and other providers have asserted that we are not entitled to do so, which have led and may lead to arbitration demands or other litigation regarding these matters.
  • For the six months ended June 30, 2014, our Retail segment pretax income declined by $177 million, or 23.0%, primarily driven by the same factors impacting our consolidated results as described above.
  • Individual Medicare Advantage membership of 2,363,000 at June 30, 2014 increased 294,300, or 14.2%, from 2,068,700 at December 31, 2013 and increased 333,300 members, or 16.4%, from 2,029,700 at June 30, 2013 reflecting net membership additions, particularly for our Health Maintenance Organization, or HMO, offerings, for the 2014 plan year.
  • Medicare stand-alone PDP membership of 3,881,100 at June 30, 2014 increased 609,400 members, or 18.6%, from 3,271,700 at December 31, 2013 and increased 660,500 members, or 20.5%, from 3,220,600 at June 30, 2013 reflecting net membership additions, primarily for our Humana-Walmart plan offering for the 2014 plan year.
  • The addition of our Florida Long-Term Support Services contracts added 17,900 members to our state-based Medicaid membership as of June 30, 2014 compared to June 30, 2013.
  • Individual commercial medical membership of 1,244,300 at June 30, 2014 increased 644,200 members, or 107.3%, from 600,100 at December 31, 2013 and increased 676,000 members, or 119.0%, from 568,300 at June 30, 2013 primarily reflecting new sales, both on-exchange and off-exchange, of plans compliant with the Health Care Reform Law. In addition, federal and state regulatory changes in December 2013 allowed certain individuals to remain in their existing underwritten health plans that are not compliant with the Health Care Reform Law, which has led to much higher than previously expected retention of our existing underwritten health plans. We believe that this is occurring at other health insurance issuers as well and will result in an overall deterioration of the risk pool in plans compliant with the Health Care Reform Law, as more previously underwritten members remain with their current health plans rather than enter the exchanges. However, we expect that the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law will mitigate this deterioration to some extent.

Employer Group Segment

  • As discussed in the detailed Employer Group segment results of operations discussion that follows, the Employer Group segment benefit ratio increased 90 basis points to 83.4% for the three months ended June 30, 2014 and increased 10 basis points to 81.1% for the six months ended June 30, 2014.
  • Fully-insured group Medicare Advantage membership of 479,700 at June 30, 2014 increased 50,600 members, or 11.8%, from 429,100 at December 31, 2013 and increased 63,100 members, or 15.1%, from 416,600 at June 30, 2013 primarily due to the January 2014 addition of a new large group account.
  • Membership in HumanaVitality®, our wellness and loyalty rewards program, rose 33.2% to 3,772,000 at June 30, 2014 from 2,831,000 at December 31, 2013 and rose 38.8% from 2,717,800 at June 30, 2013 primarily due to the addition of group Medicare members as well as individual Medicare Advantage and fully-insured individual commercial medical membership growth.

Healthcare Services Segment

  • As discussed in the detailed Healthcare Services segment results of operations discussion that follows, our Healthcare Services segment pretax income improved 66.1% for the 2014 quarter as compared to the 2013 quarter and 61.6% for the 2014 period as compared to the 2013 period primarily due to revenue growth and pretax income contribution from our pharmacy solutions and home based services businesses as they serve our growing medical membership.
  • Programs to enhance the quality of care for members are key elements of our integrated care delivery model. We have accelerated our process for identifying and reaching out to members in need of clinical intervention. At June 30, 2014, we had approximately 344,500 members with complex chronic conditions in the Humana Chronic Care Program, a 22.9% increase compared with approximately 280,200 members at December 31, 2013, and an increase of 62.5% compared with approximately 212,000 members at June 30, 2013. These increases reflect enhanced predictive modeling capabilities and focus on proactive clinical outreach and member engagement, particularly for our Medicare Advantage membership. We believe these initiatives lead to better health outcomes for our members and lower health care costs.

Other Businesses

  • Year-over-year comparisons within Other Businesses are impacted by the loss of our Medicaid contracts in Puerto Rico effective September 30, 2013 and a reduction in benefits expense for the six months ended June 30, 2013 related to a favorable settlement of contract claims with the United States Department of Defense, or DoD, associated with previously disclosed litigation.

Health Care Reform

The Health Care Reform Law enacted significant reforms to various aspects of the U.S. health insurance industry. While regulations and interpretive guidance on many provisions of the Health Care Reform Law have been issued to date by the Department of Health and Human Services, or HHS, the Department of Labor, the Treasury Department, and the National Association of Insurance Commissioners, or NAIC, there are certain provisions of the law that will require additional guidance and clarification in the form of regulations and interpretations in order to fully understand the impact of the law on our overall business.

Implementation dates of the Health Care Reform Law began in September 2010 and will continue through 2018, and many aspects of the Health Care Reform Law are already effective and have been implemented by us. Certain significant provisions of the Health Care Reform Law include, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally-facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, an annual insurance industry premium-based assessment, and a three-year commercial reinsurance fee. The following outlines certain provisions of the Health Care Reform Law:

  • Currently Effective with Phased-In Implementation: In 2012, additional cuts to Medicare Advantage plan payment benchmarks began to take effect (with plan payment benchmarks ultimately ranging from 95% in high-cost areas to 115% in low-cost areas of Medicare fee-for-service rates), with changes being phased-in over two to six years, depending on the level of payment reduction in a county. In addition, since 2011 the gap in coverage for Medicare Part D prescription drug coverage has been incrementally closing.

Certain provisions in the Health Care Reform Law tie Medicare Advantage premiums to the achievement of certain quality performance measures (Star Ratings). Beginning in 2012, Medicare Advantage plans with an overall Star Rating of three or more stars (out of five) were eligible for a quality bonus in their basic premium rates. By law, quality bonuses were limited to the few plans that achieved four or more stars as an overall rating, but CMS, through its demonstration authority, expanded the quality bonus to three Star plans for a three-year period through 2014. Beginning in 2015, quality bonus amounts will be determined by the provisions in the Health Care Reform Law. In part, this means that plans must have a Star Rating of four or higher to qualify for bonus money. Star Ratings issued by CMS in October 2013 indicated that 55% to 60% of our Medicare Advantage members are now in plans that will qualify for quality bonus payments in 2015, down from 99% in 2014, primarily due to an increase in the required minimum overall Star program rating from three stars in 2014 to four stars in 2015. Beginning in 2015, plans must have a Star Rating of four or higher to qualify for quality bonuses in the basic premium rates. We have 18 Medicare Advantage plans that achieved a rating of four or more stars, an increase of 50% from the previous year. We are offering nine Medicare Advantage plans that achieved a 4.5 Star Rating. Plans that earn an overall Star Rating of five continue to be eligible to enroll members year round. Notwithstanding successful historical efforts to improve our Star Ratings and other quality measures, there can be no assurances that we will be successful in maintaining or improving our Star Ratings in future years. Additionally, as a result of the expiration of a CMS quality bonus demonstration, for plans that maintain a four Star or higher rating in 2015, other provisions of the Health Care Reform Law may, in certain areas of the country, reduce the amount of the quality bonus that is added to the basic premium rate. Accordingly, our plans may not be eligible for full level quality bonuses, which, in isolation, could adversely affect the benefits such plans can offer, reduce membership, and/or reduce profit margins.

In addition, on March 31, 2014, with certain exceptions, we completed the initial open enrollment period for plans offered through federally-facilitated, federal-state partnerships or state-based exchanges for individuals in certain metropolitan areas in the 14 states where we have public exchange offerings.

  • Newly Effective in 2014: Beginning in 2014, the Health Care Reform Law requires: all individual and group health plans to guarantee issuance and renew coverage without pre-existing condition exclusions or health-status rating adjustments; the elimination of annual limits on coverage on certain benefits; the establishment of federally-facilitated, federal-state partnerships or state-based exchanges for individuals and small employers (with up to 100 employees) coupled with programs designed to spread risk among insurers; the introduction of plan designs based on set actuarial values; the establishment of a minimum benefit ratio of 85% for Medicare Advantage plans; and insurance industry assessments, including an annual health insurance industry fee and a three-year $25 billion industry wide commercial reinsurance fee. The annual health insurance industry fee levied on the insurance industry is $8 billion in 2014 with increasing annual amounts thereafter, growing to $14 billion by 2017, and is not deductible for income tax purposes, which will significantly increase our effective income tax rate in 2014 to approximately 46% to 47%. In addition, statutory accounting for the health insurance industry fee requires us to restrict surplus in the year preceding payment of the health insurance industry fee beginning in 2014. Accordingly, in addition to recording the full-year 2014 assessment in the first quarter of 2014, we are required to restrict surplus for the 2015 assessment ratably in 2014. In 2014, we expect to pay the federal government approximately $560 million for the annual health insurance industry fee. In 2015, the health insurance industry fee increases by 41% for the industry taken as a whole. Accordingly, absent changes in market share, we would expect a similar increase in our fee in 2015.

The Health Care Reform Law also specifies benefit design guidelines, limits rating and pricing practices, encourages additional competition from the establishment of two multi-state plans (one not-for-profit; one for-profit) administered through the Office of Personnel Management, and expands eligibility for Medicaid programs. In addition, the Health Care Reform Law has increased and will continue to increase federal oversight of health plan premium rates and could adversely affect our ability to appropriately adjust health plan premiums on a timely basis. Financing for these reforms comes, in part, from material additional fees and taxes on us (as discussed above) and other health plans and individuals beginning in 2014, as well as reductions in certain levels of payments to us and other health plans under Medicare as described in this report.

As discussed above, implementing regulations and related interpretive guidance continue to be issued on certain provisions of the Health Care Reform Law. Given the breadth of possible changes and the uncertainties of interpretation, implementation, and timing of these changes, the Health Care Reform Law has and will change the way we do business, impacting our pricing, benefit design, product mix, geographic mix, and distribution channels. The response of other companies to the Health Care Reform Law and adjustments to their and our offerings could cause meaningful disruption in local health care markets. It is reasonably possible that the Health Care Reform Law and related regulations, as well as future legislative changes, including legislative restrictions on our ability to manage our provider network or otherwise operate our business, or regulatory restrictions on profitability, including by comparison of our Medicare Advantage profitability to our non-Medicare Advantage business profitability and a requirement that they remain within certain ranges of each other, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with the non-deductible health insurance industry fee and other assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows (including the receipt of amounts due under the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law in 2015 related to claims paid in 2014). If we are unable to adjust our business model to address the non-deductible health insurance industry fee and other assessments, including the three-year commercial reinsurance fee, such as through the reduction of our operating costs or adjustments to premium pricing or benefit design, there can be no assurance that the non-deductible health insurance industry fee and other assessments would not have a material adverse effect on our results of operations, financial position, and cash flows.

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and behavioral health services, to our Retail and Employer Group customers and are described in Note 12 to the condensed consolidated financial statements.

Comparison of Results of Operations for 2014 and 2013

The following discussion primarily deals with our results of operations for the three months ended June 30, 2014, or the 2014 quarter, the three months ended June 30, 2013, or the 2013 quarter, the six months ended June 30, 2014, or the 2014 period, and the six months ended June 30, 2013, or the 2013 period.

Consolidated

(dollars in millions, except per common share results)

Revenues: Premiums: For the three months ended June 30, 2014 2013 Change Dollars Percentage
Retail $8,598 $6,766 $1,832 27.1%
Employer Group 2,964 2,710 254 9.4%
Other Businesses 22 225 (203) (90.2)%
Total premiums 11,584 9,701 1,883 19.4%
Services:
Retail 13 2 11 550%
Employer Group 87 87 — —%
Healthcare Services 332 325 7 2.2%
Other Businesses 114 114 — —%
Total services 546 528 18 3.4%
Investment income 92 92 — —%
Total revenues 12,222 10,321 1,901 18.4%
Operating expenses:
Benefits 9,627 8,091 1,536 19.0%
Operating costs 1,835 1,461 374 25.6%
Depreciation and amortization 79 80 (1) (1.3)%
Total operating expenses 11,541 9,632 1,909 19.8%
Income from operations 681 689 (8) (1.2)%
Interest expense 35 35 — —%
Income before income taxes 646 654 (8) (1.2)%
Provision for income taxes 302 234 68 29.1%
Net income $344 $420 $(76) (18.1)%
Diluted earnings per common share $2.19 $2.63 $(0.44) (16.7)%
Benefit ratio(a) 83.1% 83.4% (0.3)%
Operating cost ratio(b) 15.1% 14.3% 0.8%
Effective tax rate 46.7% 35.7% 11.0%

(a) Represents total benefits expense as a percentage of premiums revenue.

(b) Represents total operating costs as a percentage of total revenues less investment income.

(dollars in millions, except per common share results)

Revenues: Premiums: For the six months ended June 30, 2014 2013 Change Dollars Percentage
Retail $16,674 $13,670 $3,004 22.0%
Employer Group 5,954 5,445 509 9.3%
Other Businesses 39 454 (415) (91.4)%
Total premiums 22,667 19,569 3,098 15.8%
Services:
Retail 27 4 23 575%
Employer Group 173 175 (2) (1.1)%
Healthcare Services 643 640 3 0.5%
Other Businesses 241 234 7 3.0%
Total services 1,084 1,053 31 2.9%
Investment income 183 185 (2) (1.1)%
Total revenues 23,934 20,807 3,127 15.0%
Operating expenses:
Benefits 18,751 16,286 2,465 15.1%
Operating costs 3,620 2,907 713 24.5%
Depreciation and amortization 161 160 1 0.6%
Total operating expenses 22,532 19,353 3,179 16.4%
Income from operations 1,402 1,454 (52) (3.6)%
Interest expense 70 70 — —%
Income before income taxes 1,332 1,384 (52) (3.8)%
Provision for income taxes 620 491 129 26.3%
Net income $712 $893 $(181) (20.3)%
Diluted earnings per common share $4.54 $5.58 $(1.04) (18.6)%
Benefit ratio(a) 82.7% 83.2% (0.5)%
Operating cost ratio(b) 15.2% 14.1% 1.1%
Effective tax rate 46.5% 35.5% 11.0%

(a) Represents total benefits expense as a percentage of premiums revenue.

(b) Represents total operating costs as a percentage of total revenues less investment income.

Summary

Net income was $344 million, or $2.19 per diluted common share, in the 2014 quarter compared to $420 million, or $2.63 per diluted common share, in the 2013 quarter. Net income was $712 million, or $4.54 per diluted common share, in the 2014 period compared to $893 million, or $5.58 per diluted common share, in the 2013 period. These decreases were primarily due to investments in health care exchanges and new state-based contracts and higher specialty prescription drug costs associated with a new treatment for Hepatitis C. These items were partially offset by membership growth in our Medicare Advantage, Medicare stand-alone PDP, and individual commercial medical offerings. Year-over-year comparisons were also negatively impacted by sequestration which became effective April 1, 2013. In addition, our diluted earnings per common share for the 2013 period included the benefit of a reduction in benefits expense related to a favorable settlement of contract claims with the DoD, partially offset by costs in the 2013 quarter associated with the loss of our Medicaid contracts in Puerto Rico. Year-over-year comparisons of diluted earnings per common share are also favorably impacted by a lower number of shares used to compute diluted earnings per common share in the 2014 quarter and period reflecting the impact of share repurchases.

Premiums

Consolidated premiums increased $1.9 billion, or 19.4%, from the 2013 quarter to $11.6 billion for the 2014 quarter and increased $3.1 billion, or 15.8%, from the 2013 period to $22.7 billion for the 2014 period. These increases are primarily due to increases in both Retail and Employer Group segment premiums mainly driven by higher average individual and group Medicare Advantage membership as well as higher individual commercial medical membership, partially offset by the impact of sequestration which became effective April 1, 2013. Premiums revenue for our Other Businesses declined primarily due to the loss of our Puerto Rico Medicaid contracts effective September 30, 2013. Average membership is calculated by summing the ending membership for each month in a period and dividing the result by the number of months in a period. Premiums revenue reflects changes in membership and average per member premiums. Items impacting average per member premiums include changes in premium rates as well as changes in the geographic mix of membership, the mix of product offerings, and the mix of benefit plans selected by our membership.

Services revenue

Consolidated services revenue increased $18 million, or 3.4%, from the 2013 quarter to $546 million for the 2014 quarter and increased $31 million, or 2.9%, from the 2013 period to $1.1 billion for the 2014 period. These increases are primarily due to an increase in services revenue in our Retail segment due to the acquisition of American Eldercare in September 2013.

Investment income

Investment income totaled $92 million for each of the 2014 quarter and 2013 quarter and was $183 million for the 2014 period as compared to $185 million for the 2013 period as higher average invested balances were more than offset by lower interest rates.

Benefits expense

Consolidated benefits expense was $9.6 billion for the 2014 quarter, an increase of $1.5 billion, or 19.0%, from the 2013 quarter. For the 2014 period, benefits expense was $18.8 billion, an increase of $2.5 billion, or 15.1%, from the 2013 period. These increases are primarily due to increases in both Retail and Employer Group segments mainly driven by higher average individual and group Medicare Advantage membership as well as higher individual commercial medical membership. We experienced favorable medical claims reserve development related to prior fiscal years of $49 million in the 2014 quarter as compared to $100 million in the 2013 quarter, and $346 million in the 2014 period as compared to $366 million in the 2013 period. These decreases primarily result from prior year claims reprocessing in the 2014 quarter and period attributable to retroactive adjustments from policy extensions mandated by the Health Care Reform Law, increased severity of 2013 claims for fully insured commercial group business, and, to a lesser extent, improvements in claims processing and front end audits in 2014.

The consolidated benefit ratio for the 2014 quarter was 83.1%, a 30 basis point decrease from the 2013 quarter. The consolidated benefit ratio for the 2014 period was 82.7%, a 50 basis point decrease from the 2013 period. The decreases in the 2014 quarter and period are primarily due to the loss of our Medicaid contracts in Puerto Rico effective September 30, 2013 which more than offset higher ratios year-over-year in the Retail and Employer Group segments.

Operating costs

Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.

Consolidated operating costs increased $374 million, or 25.6%, during the 2014 quarter compared to the 2013 quarter and increased $713 million, or 24.5%, during the 2014 period compared to the 2013 period. These increases are primarily due to costs mandated by the Health Care Reform Law, including the non-deductible health insurance industry fee, higher commission expenses for new Medicare Advantage members, and investments in health care exchanges and new state-based contracts.

The consolidated operating cost ratio for the 2014 quarter was 15.1%, increasing 80 basis points from the 2013 quarter. The consolidated operating cost ratio for the 2014 period was 15.2%, increasing 110 basis points from the 2014 period. These increases are primarily due to increases in the operating cost ratios in our Retail and Employer Group segments due to the same factors impacting consolidated operating costs as described above.

Depreciation and amortization

Depreciation and amortization for the 2014 quarter totaled $79 million, comparable to $80 million for the 2013 quarter. For the 2014 period, depreciation and amortization of $161 million compared to $160 million for the 2013 period.

Interest expense

Interest expense of $35 million for the 2014 quarter and $70 million for the 2014 period was comparable to that of the 2013 quarter and 2013 period, respectively.

Income Taxes

Our effective tax rate during the 2014 quarter was 46.7% compared to the effective tax rate of 35.7% in the 2013 quarter. For the 2014 period our effective tax rate was 46.5% compared to the effective tax rate of 35.5% for the 2013 period. The non-deductible nature of the health insurance industry fee levied on the insurance industry beginning in 2014 as mandated by the Health Care Reform Law increased our effective tax rate by approximately 9 percentage points for the 2014 period. In addition, the effective tax for the 2013 quarter and 2013 period includes the beneficial effect of a change in our estimated tax liability associated with limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law.

Retail Segment

Membership: Medical membership: June 30, 2014 2013 Change Members Percentage
Individual Medicare Advantage 2,363,000 2,029,700 333,300 16.4%
Medicare stand-alone PDP 3,881,100 3,220,600 660,500 20.5%
Total Retail Medicare 6,244,100 5,250,300 993,800 18.9%
Individual commercial 1,244,300 568,300 676,000 119.0%
State-based Medicaid 163,000 70,600 92,400 130.9%
Total Retail medical members 7,651,400 5,889,200 1,762,200 29.9%
Individual specialty membership (a) 1,229,500 1,011,700 217,800 21.5%

(a) Specialty products include dental, vision, and other supplemental health and financial protection products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.

(in millions)

Premiums and Services Revenue: Premiums: For the three months ended June 30, 2014 2013 Change Dollars Percentage
Individual Medicare Advantage $6,475 $5,572 $903 16.2%
Medicare stand-alone PDP 939 785 154 19.6%
Total Retail Medicare 7,414 6,357 1,057 16.6%
Individual commercial 912 285 627 220.0%
State-based Medicaid 206 72 134 186.1%
Individual specialty 66 52 14 26.9%
Total premiums 8,598 6,766 1,832 27.1%
Services 13 2 11 550%
Total premiums and services revenue $8,611 $6,768 $1,843 27.2%
Income before income taxes $329 $418 $(89) (21.3)%
Benefit ratio 84.7% 84.2% 0.5%
Operating cost ratio 11.4% 9.5% 1.9%

39

(in millions)

Premiums and Services Revenue: Premiums: For the six months ended June 30, 2014 2013 Change Dollars Percentage
Individual Medicare Advantage $12,935 $11,308 $1,627 14.4%
Medicare stand-alone PDP 1,802 1,546 256 16.6%
Total Retail Medicare 14,737 12,854 1,883 14.6%
Individual commercial 1,437 564 873 154.8%
State-based Medicaid 375 151 224 148.3%
Individual specialty 125 101 24 23.8%
Total premiums 16,674 13,670 3,004 22.0%
Services 27 4 23 575%
Total premiums and services revenue $16,701 $13,674 $3,027 22.1%
Income before income taxes $591 $768 $(177) (23.0)%
Benefit ratio 85.0% 85.0% —%
Operating cost ratio 11.4% 9.2% 2.2%

Pretax Results

  • Retail segment pretax income was $329 million in the 2014 quarter, a decrease of $89 million, or 21.3%, compared to $418 million in the 2013 quarter. Retail segment pretax income was $591 million in the 2014 period, a decrease of $177 million, or 23.0%, compared to $768 million in the 2013 period. These decreases are primarily driven by higher operating cost ratios in the 2014 quarter and period as well as a higher benefit ratio in the 2014 quarter.

Enrollment

  • Individual Medicare Advantage membership increased 333,300 members, or 16.4%, from June 30, 2013 to June 30, 2014 reflecting net membership additions, particularly for our HMO offerings, for the 2014 plan year.
  • Medicare stand-alone PDP membership increased 660,500 members, or 20.5%, from June 30, 2013 to June 30, 2014 reflecting net membership additions, primarily for our Humana-Walmart plan offering, for the 2014 plan year.
  • Individual commercial medical membership increased 676,000 members, or 119.0%, from June 30, 2013 to June 30, 2014 primarily reflecting new sales, both on-exchange and off-exchange, of plans compliant with the Health Care Reform Law.
  • State-based Medicaid membership increased 92,400 members, or 130.9%, from June 30, 2013 to June 30, 2014, primarily driven by the addition of our Kentucky Medicaid contract and Florida Long-Term Support Services contracts.
  • Individual specialty membership increased 217,800 members, or 21.5%, from June 30, 2013 to June 30, 2014 primarily driven by increased membership in dental and vision offerings.

Premiums

  • Retail segment premiums increased $1.8 billion, or 27.1%, from the 2013 quarter to the 2014 quarter and increased $3.0 billion, or 22.0% from the 2013 period to the 2014 period primarily due to a 16.2% and 15.9% increase for the quarter and period, respectively, in average individual Medicare Advantage membership as well as individual commercial medical membership growth, primarily on the health care exchanges, that more than offset the impact of sequestration. Individual Medicare Advantage per member premiums remained relatively flat in the 2014 quarter as compared to the 2013 quarter and decreased approximately 1.3% in the 2014 period compared to the 2013 period primarily reflecting the impact of sequestration which became effective April 1, 2013.

Benefits expense

  • The Retail segment benefit ratio increased 50 basis points from 84.2% in the 2013 quarter to 84.7% in the 2014 quarter and remained flat at 85.0% in the 2014 and 2013 periods. The increase in the 2014 quarter primarily was due to lower prior-period medical claims reserve development, higher specialty prescription drug costs associated with a new treatment for Hepatitis C, and the new health care exchange offerings in the 2014 quarter. New individual commercial medical members in plans compliant with the Health Care Reform Law generally are expected to carry a higher benefit ratio than our previously underwritten membership. These items were partially offset by returns on investments in clinical programs and the inclusion of the health insurance industry fee in the pricing of our products.
  • The Retail segment’s pretax income for the 2014 quarter included the beneficial effect of $42 million in favorable prior-period medical claims reserve development versus $72 million in the 2013 quarter. The decrease in the 2014 quarter is primarily due to prior year claims reprocessing in the 2014 quarter attributable to retroactive adjustments from policy extensions mandated by the Health Care Reform Law and, to a lesser extent, improvements in claims processing and front end audits in 2014. For the 2014 period, the Retail segment’s benefit expense included the beneficial effect of $264 million in favorable prior-period medical claims reserve development versus $250 million in the 2013 period. This favorable prior-period medical claims reserve development decreased the Retail segment benefit ratio by approximately 50 basis points in the 2014 quarter versus approximately 110 basis points in the 2013 quarter, and by approximately 160 basis points in the 2014 period versus approximately 180 basis points in the 2013 period.

Operating costs

  • The Retail segment operating cost ratio of 11.4% for the 2014 quarter increased 190 basis points from 9.5% for the 2013 quarter. The Retail segment operating cost ratio of 11.4% for the 2014 period increased 220 basis points from 9.2% for the 2013 period. These increases are primarily due to the non-deductible health insurance industry fee mandated by the Health Care Reform Law, investments in health care exchanges and new state-based contracts, and higher Medicare Advantage marketing and distribution costs, partially offset by scale efficiencies from Medicare Advantage and individual commercial medical membership growth.

Employer Group Segment

Membership: Medical membership: June 30, 2014 2013 Change Members Percentage
Group Medicare Advantage 479,700 416,600 63,100 15.1%
Group Medicare stand-alone PDP 4,400 3,700 700 18.9%
Total group Medicare 484,100 420,300 63,800 15.2%
Fully-insured commercial group 1,210,100 1,196,100 14,000 1.2%
ASO 1,120,100 1,199,600 (79,500) (6.6)%
Total group medical members 2,814,300 2,816,000 (1,700) (0.1)%
Group specialty membership (a) 6,576,000 7,256,800 (680,800) (9.4)%

(a) Specialty products include dental, vision, and voluntary benefit products. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.

(in millions)

Premiums and Services Revenue: Premiums: For the three months ended June 30, 2014 2013 Change Dollars Percentage
Group Medicare Advantage $1,366 $1,160 $206 17.8%
Group Medicare stand-alone PDP 2 2 — —%
Total group Medicare 1,368 1,162 206 17.7%
Fully-insured commercial group 1,321 1,273 48 3.8%
Group specialty 275 275 — —%
Total premiums 2,964 2,710 254 9.4%
Services 87 87 — —%
Total premiums and services revenue $3,051 $2,797 $254 9.1%
Income before income taxes $89 $134 $(45) (33.6)%
Benefit ratio 83.4% 82.5% 0.9%
Operating cost ratio 16.0% 15.1% 0.9%

42

(in millions)

Premiums and Services Revenue: Premiums: For the six months ended June 30, 2014 2013 Change Dollars Percentage
Group Medicare Advantage $2,750 $2,350 $400 17.0%
Group Medicare stand-alone PDP 4 4 — —%
Total group Medicare 2,754 2,354 400 17.0%
Fully-insured commercial group 2,650 2,541 109 4.3%
Group specialty 550 550 — —%
Total premiums 5,954 5,445 509 9.3%
Services 173 175 (2) (1.1)%
Total premiums and services revenue $6,127 $5,620 $507 9.0%
Income before income taxes $315 $346 $(31) (9.0)%
Benefit ratio 81.1% 81.0% 0.1%
Operating cost ratio 16.1% 15.2% 0.9%

Pretax Results

  • Employer Group segment pretax income decreased $45 million, or 33.6%, to $89 million in the 2014 quarter, and decreased $31 million, or 9.0%, to $315 million for the 2014 period primarily due to increases in both the benefit and operating cost ratios as described below.

Enrollment

  • Fully-insured group Medicare Advantage membership increased 63,100 members, or 15.1%, from June 30, 2013 to June 30, 2014 primarily due to the addition of a new large account.
  • Fully-insured commercial group medical membership remained relatively unchanged, increasing 14,000 members, or 1.2%, from June 30, 2013 to June 30, 2014 as an increase in small group business membership was generally offset by lower membership in large group accounts.
  • Group ASO commercial medical membership decreased 79,500 members, or 6.6%, from June 30, 2013 to June 30, 2014 primarily due to continued pricing discipline in a highly competitive environment for self-funded accounts.
  • Group specialty membership decreased 680,800 members, or 9.4%, from June 30, 2013 to June 30, 2014 primarily due to declines in dental and vision membership related to our planned discontinuance of certain unprofitable product distribution partnerships.

Premiums

  • Employer Group segment premiums increased $254 million, or 9.4%, to $3.0 billion for the 2014 quarter, and increased $509 million, or 9.3%, to $6.0 billion for the 2014 period primarily due to higher average group Medicare Advantage membership.

Benefits expense

  • The Employer Group segment benefit ratio increased 90 basis points from 82.5% in the 2013 quarter to 83.4% in the 2014 quarter, and increased 10 basis points from 81.0% in the 2013 period to 81.1% in the 2014 period. The increases are primarily due to lower favorable prior-period medical claims reserve development and higher specialty prescription drug costs associated with a new treatment for Hepatitis C, partially offset by the inclusion of the health insurance industry fee and other fees mandated by the Health Care Reform Law in our pricing.

The Employer Group segment’s pretax income for the 2014 quarter included the beneficial effect of $9 million in favorable prior-period medical claims reserve development versus $27 million in the 2013 quarter. The decline in favorable prior-period medical claims reserve development primarily reflects higher 2013 claims severity for our fully-insured commercial group business and, to a lesser extent, improvements in claims processing and front end audits in 2014. For the 2014 period, the Employer Group segment’s pretax income included the beneficial effect of $83 million in favorable prior-period medical claims reserve development versus $113 million in the 2013 period. This favorable prior-period medical claims reserve development decreased the Employer Group segment benefit ratio by approximately 30 basis points in the 2014 quarter versus approximately 100 basis points in the 2013 quarter, and by approximately 140 basis points in the 2014 period versus 210 basis points in the 2013 period.

Operating costs

  • The Employer Group segment operating cost ratio of 16.0% for the 2014 quarter increased 90 basis points from 15.1% for the 2013 quarter. For the 2014 period, the Employer Group segment operating cost ratio of 16.1% increased 90 basis points from 15.2% for the 2013 period. The increases primarily reflect the impact of the non-deductible health insurance industry fee and other fees mandated by the Health Care Reform Law, partially offset by an increase in group Medicare Advantage membership which generally carries a lower operating cost ratio than our commercial group medical membership.

Healthcare Services Segment

(in millions)

Revenues: Services: For the three months ended June 30, 2014 2013 Change Dollars Percentage
Provider services $282 $289 $(7) (2.4)%
Home based services 25 23 2 8.7%
Pharmacy solutions 25 13 12 92.3%
Total services revenues 332 325 7 2.2%
Intersegment revenues:
Pharmacy solutions 4,204 3,212 992 30.9%
Provider services 260 271 (11) (4.1)%
Home based services 138 72 66 91.7%
Integrated behavioral health services 33 31 2 6.5%
Total intersegment revenues 4,635 3,586 1,049 29.3%
Total services and intersegment revenues $4,967 $3,911 $1,056 27.0%
Income before income taxes $206 $124 $82 66.1%
Operating cost ratio 95.1% 95.9% (0.8)%

44

(in millions)

Revenues: Services: For the six months ended June 30, 2014 2013 Change Dollars Percentage
Provider services $549 $571 $(22) (3.9)%
Home based services 48 46 2 4.3%
Pharmacy solutions 46 22 24 109.1%
Integrated behavioral health services — 1 (1) (100.0)%
Total services revenues 643 640 3 0.5%
Intersegment revenues:
Pharmacy solutions 8,061 6,297 1,764 28.0%
Provider services 552 550 2 0.4%
Home based services 256 132 124 93.9%
Integrated behavioral health services 66 62 4 6.5%
Total intersegment revenues 8,935 7,041 1,894 26.9%
Total services and intersegment revenues $9,578 $7,681 $1,897 24.7%
Income before income taxes $391 $242 $149 61.6%
Operating cost ratio 95.2% 95.9% (0.7)%

Pretax results

  • Healthcare Services segment pretax income of $206 million for the 2014 quarter increased $82 million, or 66.1%, from $124 million for the 2013 quarter. For the 2014 period, the Healthcare Services segment pretax income of $391 million increased $149 million, or 61.6%, from $242 million for the 2013 period. These increases are primarily due to revenue growth and pretax income contribution from our pharmacy solutions and home based services businesses as they serve our growing medical membership.

Script Volume

  • Humana Pharmacy Solutions® script volumes for Retail and Employer Group segment membership increased to approximately 82 million in the 2014 quarter, up 20% versus scripts of approximately 68 million in the 2013 quarter. For the 2014 period, script volumes for Retail and Employer Group segment membership increased to approximately 160 million, up 19% versus scripts of approximately 134 million in the 2013 period. These increases primarily reflect growth associated with higher average medical membership for the 2014 quarter and period than in the 2013 quarter and period.

Services revenue

  • Services revenue for the 2014 quarter and period were relatively unchanged from the 2013 quarter and period, increasing $7 million, or 2.2%, and $3 million, or 0.5%, respectively.

Intersegment revenues

  • Intersegment revenues increased $1.0 billion, or 29.3%, from the 2013 quarter to $4.6 billion for the 2014 quarter and increased $1.9 billion, or 26.9%, from the 2013 period to $8.9 billion primarily due to growth in our pharmacy solutions and home based services businesses as they serve our growing medical membership.

Operating costs

  • The Healthcare Services segment operating cost ratio of 95.1% for the 2014 quarter decreased 80 basis points from 95.9% for the 2013 quarter. The Healthcare Services segment operating ratio of 95.2% for the 2014 period decreased 70 basis points from 95.9% for the 2013 period. The decreases are primarily due to scale efficiencies associated with growth in our pharmacy solutions business.

Other Businesses

Pretax income for our Other Businesses of $17 million for the 2014 quarter increased $47 million compared to a pretax loss of $30 million for the 2013 quarter. For the 2014 period, pretax income of $42 million increased $14 million compared to pretax income of $28 million in the 2013 period. These increases primarily were due to costs in the 2013 quarter and period associated with the loss of our Medicaid contracts in Puerto Rico, as discussed previously, partially offset by a reduction in benefits expense in the 2013 period related to a favorable settlement of contract claims with the DoD associated with previously disclosed litigation.

Liquidity

Our primary sources of cash include receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities and borrowings. Our primary uses of cash include disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. Because premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including taxes and assessments. The use of operating cash flows may be limited by regulatory requirements which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of operating cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by Departments of Insurance.

For 2014, the effect of the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law are impacting the timing of our operating cash flows, as we expect to build a receivable in 2014 that will be collected in 2015. It is reasonably possible that the receivable could be material to our operating cash flow for the full year 2014. For the full year 2014, we expect our operating cash flows to decline from 2013. In addition, we expect our 2014 financing cash flows to be negatively impacted by the timing of payments to and receipts from CMS associated with Medicare Part D reinsurance subsidies for which we do not assume risk. We are experiencing higher specialty prescription drug costs associated with a new treatment for Hepatitis C than were contemplated in our bids which is resulting in higher reinsurance subsidy receivable balances in 2014 that will be settled in 2015 under the terms of our contracts with CMS. Any amounts receivable or payable associated with these risk limiting programs and CMS subsidies may have an impact on subsidiary liquidity, with any temporary shortfalls funded by the parent company.

For additional information on our liquidity risk, please refer to the section entitled “Risk Factors” in this report and in our 2013 Form 10-K.

Cash and cash equivalents increased to $1.6 billion at June 30, 2014 from $1.1 billion at December 31, 2013. The change in cash and cash equivalents for the six months ended June 30, 2014 and 2013 is summarized as follows:

(in millions)

2014 2013
Net cash provided by operating activities $471 $585
Net cash provided by (used in) investing activities 404 (148)
Net cash used in financing activities (420) (224)
Increase in cash and cash equivalents $455 $213

Cash Flow from Operating Activities

The decrease in operating cash flows from the 2013 period to the 2014 period primarily results from lower earnings and the timing of working capital items. The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. We illustrate these changes with the following summaries of benefits payable and receivables.

The detail of benefits payable was as follows at June 30, 2014 and December 31, 2013:

(in millions)

June 30, 2014 December 31, 2013 2014 Period Change 2013 Period Change
IBNR (1) $3,242 $2,586 $656 $215
Reported claims in process (2) 635 381 254 168
Other benefits payable (3) 901 926 (25) (5)
Total benefits payable $4,778 $3,893 $885 $378

(1) IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i.e. a shorter time span results in a lower IBNR).

(2) Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff.

(3) Other benefits payable primarily include amounts owed to providers under capitated and risk sharing arrangements.

The increase in benefits payable from December 31, 2013 to June 30, 2014 primarily was due to an increase in IBNR, primarily as a result of Medicare Advantage membership growth, and an increase in the amount of processed but unpaid claims, including amounts due to our pharmacy benefit administrator, which fluctuate due to month-end cutoff. The increase in benefits payable from December 31, 2012 to June 30, 2013 primarily was due to the same factors resulting in the increase in benefits payable from December 31, 2013 to June 30, 2014 described above.

The detail of total net receivables was as follows at June 30, 2014 and December 31, 2013:

(in millions)

June 30, 2014 December 31, 2013 2014 Period Change 2013 Period Change
Medicare $1,681 $576 $1,105 $786
Commercial and other 418 405 13 42
Military services 96 87 9 47
Allowance for doubtful accounts (121) (118) (3) (15)
Total net receivables $2,074 $950 1,124 860
Reconciliation to cash flow statement:
Disposition of receivables from sale of business 13 —
Change in receivables per cash flow statement resulting in cash from operations $1,137 $860

The increases in Medicare receivables reflect the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. Significant collections occur with the final and mid-year settlements with CMS in July and August, respectively. In connection with our July 2014 payment from CMS, we collected $558 million associated with the final Medicare risk-adjustment payment for the 2013 plan year. In addition, in connection with our August 2014 payment from CMS, we expect to collect $794 million associated with the mid-year Medicare risk-adjustment payment.

Military services receivables at June 30, 2014 and December 31, 2013 primarily consist of administrative services only fees owed from the federal government for administrative services provided under our TRICARE South Region contract and final settlement balances due under our previous TRICARE South Region contract. Payments of the federal government’s claims and related reimbursements under our current TRICARE South Region contract are classified with receipts (withdrawals) from contract deposits as a financing item in our consolidated statements of cash flows.

Many provisions of the Health Care Reform Law became effective in 2014, including the commercial risk adjustment, risk corridor, and reinsurance provisions as well as the non-deductible health insurance industry fee. As discussed previously, the timing of payments and receipts associated with these provisions will impact our operating cash flows as we expect to build a receivable in 2014 that will be collected in 2015. The net receivable balance associated with the 3Rs was approximately $240 million at June 30, 2014.

In addition to the timing of receipts for premiums and services revenues, payments of benefits expense, and amounts due under the risk limiting and health insurance industry fee provisions of the Health Care Reform Law, other working capital items impacting operating cash flows primarily resulted from the timing of payments for the Medicare Part D risk corridor provisions of our contracts with CMS and changes in the timing of the collection of pharmacy rebates.

Cash Flow from Investing Activities

Proceeds from sales and maturities of investment securities exceeded purchases by $551 million in the 2014 period. These net proceeds were used to fund normal working capital needs due to the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model coupled with an increase in receivables in 2014 that will be collected in 2015 associated with the commercial risk adjustment, risk corridor, and reinsurance provisions of the Health Care Reform Law in addition to the timing of payments to and receipts from CMS associated with Medicare Part D reinsurance subsidies, as discussed previously. In the 2013 period we reinvested a portion of our operating cash flows in investment securities, primarily investment-grade fixed income securities, totaling $18 million.

Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our provider services operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were $216 million in the 2014 period and $187 million in the 2013 period reflecting increased spending associated with growth in our provider services and pharmacy businesses in our Healthcare Services segment. Excluding acquisitions, we expect total capital expenditures in 2014 in a range of approximately $525 million to $575 million.

Cash Flow from Financing Activities

Claims payments were $122 million higher than receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk during the 2014 period. During the 2013 period, receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were $144 million higher than claims payments. As discussed previously, we expect our 2014 financing cash flows to be negatively impacted by the timing of payments to and receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk. We are experiencing higher specialty prescription drug costs associated with a new treatment for Hepatitis C than were contemplated in our bids which is resulting in higher subsidy receivable balances in 2014 that will be settled in 2015 under the terms of our contracts with CMS. Our net receivable for CMS subsidies and brand name prescription drug discounts was $835 million at June 30, 2014 compared to $414 million at June 30, 2013 and $713 million at December 31, 2013. Refer to Note 6 to the condensed consolidated financial statements.

Under our administrative services only TRICARE South Region contract, health care cost payments for which we do not assume risk exceeded reimbursements from the federal government by $29 million during the 2014 period compared to $12 million during the 2013 period.

Receipts from HHS associated with cost sharing provisions of the Health Care Reform Law for which we do not assume risk were $24 million higher than claims payments.

We repurchased 0.91 million shares for $112 million in the 2014 period and 2.83 million shares for $211 million in the 2013 period under share repurchase plans authorized by the Board of Directors. We also acquired common shares in connection with employee stock plans for an aggregate cost of $40 million in the 2014 period and $20 million in the 2013 period.

During the 2014 period we paid dividends to stockholders of $86 million as compared to $83 million in the 2013 period, as discussed further below.

Future Sources and Uses of Liquidity

Dividends

The following table provides details of dividend payments in 2013 and 2014 under our Board approved quarterly cash dividend policy:

(in millions)

Record Date 2013 payments Payment Date Amount per Share Total Amount
12/31/2012 1/25/2013 $0.26 $42
3/28/2013 4/26/2013 $0.26 $41
6/28/2013 7/26/2013 $0.27 $42
9/30/2013 10/25/2013 $0.27 $42
2014 payments
12/31/2013 1/31/2014 $0.27 $42
3/31/2014 4/25/2014 $0.27 $42
6/30/2014 7/25/2014 $0.28 $43

49

Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

Stock Repurchases

In April 2014, the Board of Directors replaced a previous share repurchase authorization of up to $1 billion (of which $569 million remained unused) with a new authorization for repurchases of up to $1 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring on June 30, 2016. Under the new share repurchase authorization, shares may be purchased from time to time at prevailing prices in the open market, by block purchases, or in privately-negotiated transactions, subject to certain regulatory restrictions on volume, pricing, and timing. During the six months ended June 30, 2014, we repurchased 0.1 million shares in open market transactions for $11 million at an average price of $113.44 under a previous share repurchase authorization and we repurchased 0.81 million shares in open market transactions for $101 million at an average price of $125.04 under the current authorization. During the six months ended June 30, 2013, we repurchased 2.83 million shares in open market transactions for $211 million at an average price of $74.67 under previous share repurchase authorizations. As of July 30, 2014, the remaining authorized amount under the new authorization totaled $899 million.

In connection with employee stock plans, we acquired 0.4 million common shares for $40 million and 0.2 million common shares for $20 million during the six months ended June 30, 2014 and 2013, respectively.

Senior Notes

We previously issued $500 million of 6.45% senior notes due June 1, 2016, $500 million of 7.20% senior notes due June 15, 2018, $300 million of 6.30% senior notes due August 1, 2018, $600 million of 3.15% senior notes due December 1, 2022, $250 million of 8.15% senior notes due June 15, 2038, and $400 million of 4.625% senior notes due December 1, 2042. The 7.20% and 8.15% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our 7.20%, 8.15%, 3.15%, and 4.625% senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances. All six series of our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount.

Credit Agreement

In July 2013, we amended and restated our 5-year $1.0 billion unsecured revolving credit agreement to, among other things, extend its maturity to July 2018 from November 2016. Under the amended and restated credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. The LIBOR spread, currently 110 basis points, varies depending on our credit ratings ranging from 90.0 to 150.0 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently 15.0 basis points, may fluctuate between 10.0 and 25.0 basis points, depending upon our credit ratings. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option.

The terms of the credit agreement include standard provisions related to conditions of borrowing, including a customary material adverse effect clause which could limit our ability to borrow additional funds. In addition, the credit agreement contains customary restrictive and financial covenants as well as customary events of default, including financial covenants regarding the maintenance of a minimum level of net worth of $7.6 billion at June 30, 2014 and a maximum leverage ratio of 3.0:1. We are in compliance with the financial covenants, with actual net worth of $10.0 billion and actual leverage ratio of 1.0:1, as measured in accordance with the credit agreement as of June 30, 2014. In addition, the credit agreement includes an uncommitted $250 million incremental loan facility.

At June 30, 2014, we had no borrowings outstanding under the credit agreement. We have outstanding letters of credit of $5 million secured under the credit agreement. No amounts have been drawn on these letters of credit. Accordingly, as of June 30, 2014, we had $995 million of remaining borrowing capacity under the credit agreement, none of which would be restricted by our financial covenant compliance requirement. We have other customary, arms-length relationships, including financial advisory and banking relationships, with some parties to the credit agreement.

Liquidity Requirements

We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.

Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at June 30, 2014 was BBB+ according to Standard & Poor’s Rating Services, or S&P, and Baa3 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $750 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $2 million, up to a maximum 100 basis points, or annual interest expense by $8 million.

In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company were $736 million at June 30, 2014 compared to $508 million at December 31, 2013. As described in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations under the section titled “Health Care Reform,” statutory accounting for the health insurance industry fee requires us to restrict surplus in the year preceding payment beginning in 2014. Therefore, in addition to recording the full-year 2014 assessment in the first quarter of 2014, we are required to restrict surplus for the 2015 assessment ratably in 2014. In 2014, we expect to pay the federal government approximately $560 million for the annual health insurance industry fee. In 2015, the health insurance industry fee increases by 41% for the industry taken as a whole. Accordingly, absent changes in market share, we would expect a similar increase in our fee in 2015.

Regulatory Requirements

Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. In most states, prior notification is provided before paying a dividend even if approval is not required. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.

Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Based on the most recently filed statutory financial statements as of March 31, 2014, our state regulated subsidiaries had aggregate statutory capital and surplus of approximately $5.5 billion, which exceeded aggregate minimum regulatory requirements of $3.6 billion. The amount of dividends that were paid to our parent company in the 2014 period was approximately $695 million in the aggregate. In addition, $219 million of dividends were paid to our parent company in July 2014, bringing the full year total through July 30, 2014 to $914 million. This compares to dividends that were paid for the full year 2013 of approximately $967 million. The year-over-year decline is a result of higher surplus requirements associated with premium growth due to increases in membership.

Market risk

As filed, 2,102 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.

Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&P credit rating of AA- at June 30, 2014. Our net unrealized position increased $251 million from a net unrealized gain position of $250 million at December 31, 2013 to a net unrealized gain position of $501 million at June 30, 2014. At June 30, 2014, we had gross unrealized losses of $43 million on our investment portfolio primarily due to an increase in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. There were no material other-than-temporary impairments during the three months ended June 30, 2014. While we believe that these impairments are temporary and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or other-than-temporary impairments may be recorded in future periods.

Duration is the time-weighted average of the present value of the bond portfolio’s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 4.4 years as of June 30, 2014 and 4.3 years as of December 31, 2013. Based on the duration, including cash equivalents, a 1% increase in interest rates would generally decrease the fair value of our securities by approximately $471 million.

Controls and procedures

As filed, 1,278 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our Principal Accounting Officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended June 30, 2014.

Based on our evaluation, our CEO, CFO, and our Principal Accounting Officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information the Company is required to disclose in its reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including, without limitation, ensuring that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 5,810 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except as set forth below, there have been no changes to the risk factors included in our 2013 Form 10-K. The following replaces in its entirety the fourth bullet under the risk factor in our 2013 Form 10-K entitled, “As a government contractor, we are exposed to risks that may materially adversely affect our business or our willingness or ability to participate in government health care programs.”

  • CMS uses a risk-adjustment model which apportions premiums paid to Medicare Advantage, or MA, plans according to health severity. The risk-adjustment model pays more for enrollees with predictably higher costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process that bases our prospective payments on a comparison of our beneficiaries’ risk scores, derived from medical diagnoses, to those enrolled in the government’s traditional fee-for-service Medicare program (referred to as “Medicare FFS”). Under the risk-adjustment methodology, all MA plans must collect and submit the necessary diagnosis code information from hospital inpatient, hospital outpatient, and physician providers to CMS within prescribed deadlines. The CMS risk-adjustment model uses this diagnosis data to calculate the risk-adjusted premium payment to MA plans. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our payment received from CMS under the actuarial risk-adjustment model. We also rely on providers to appropriately document all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. These compliance efforts include the internal contract level audits described in more detail below.

CMS is continuing to perform audits of various companies’ selected MA contracts related to this risk adjustment diagnosis data. These audits are referred to herein as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices which influence the calculation of premium payments to MA plans.

On February 24, 2012, CMS released a “Notice of Final Payment Error Calculation Methodology for Part C Medicare Advantage Risk Adjustment Data Validation (RADV) Contract-Level Audits”. The final payment error calculation methodology provides that, in calculating the economic impact of audit results for an MA contract, if any, the results of the audit sample will be extrapolated to the entire MA contract based upon a comparison to “benchmark” audit data in Medicare FFS (which we refer to as the “FFS Adjuster”). This comparison to a Medicare FFS benchmark audit is necessary to determine the economic impact, if any, of audit results because the government program data set, including any attendant errors that are present in that data set, provides the basis for MA plans’ risk adjustment to payment rates.

The final methodology, including the first application of extrapolated audit results to determine audit settlements, is expected to be applied to the next round of RADV contract level audits to be conducted on 2011 premium payments. Selected MA contracts will be notified of an audit at some point after the close of the final reconciliation for the payment year being audited. The final reconciliation occurs in August of the calendar year following the payment year. We have been notified that certain of our Medicare Advantage contracts have been selected for audit for contract year 2011.

Estimated audit settlements are recorded as a reduction of premiums revenue in our consolidated statements of income, based upon available information. During 2012, we completed internal contract level audits of certain 2011 contracts based on the RADV audit methodology prescribed by CMS. Included in these internal contract level audits was an audit of our Private Fee-For-Service business which we used to represent a proxy of the benchmark audit data in Medicare FFS which has not yet been released. We based our accrual of estimated audit settlements for contract years 2011 (the first year that application of extrapolated audit results is applicable) and 2012 on the results of these internal contract level audits for contract year 2011. Estimates derived from these results were not material to our results of operations, financial position, or cash flows. However, as indicated, we are awaiting additional guidance from CMS regarding the benchmark audit data in Medicare FFS. Accordingly, we cannot determine whether such audits will have a material adverse effect on our results of operations, financial position, or cash flows.

In addition, CMS’ recent comments in formalized guidance regarding “overpayments” to Medicare Advantage plans appear to be inconsistent with the Agency’s prior RADV audit guidance. These statements, contained in the preamble to CMS’ final rule release regarding Medicare Advantage and Part D prescription drug benefit program regulations for Contract Year 2015, appear to equate each Medicare Advantage risk adjustment data error with an “overpayment” without reconciliation to the principles underlying the FFS Adjuster referenced above. We will continue to work with CMS to ensure that Medicare Advantage plans are paid accurately and that payment model principles are in accordance with the requirements of the Social Security Act, which if not implemented correctly, could have material adverse effect on our results of operations, financial position, or cash flows.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-04-01 to 2014-06-30$12.22bnus-gaap:Revenues
Revenue6 months2014-01-01 to 2014-06-30$23.93bnus-gaap:Revenues
Selling, general and administrative3 months2014-04-01 to 2014-06-30$1.83bnus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2014-01-01 to 2014-06-30$3.62bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2014-04-01 to 2014-06-30$681.0mus-gaap:OperatingIncomeLoss
Operating income6 months2014-01-01 to 2014-06-30$1.40bnus-gaap:OperatingIncomeLoss
Interest expense3 months2014-04-01 to 2014-06-30$35.0mus-gaap:InterestExpense
Interest expense6 months2014-01-01 to 2014-06-30$70.0mus-gaap:InterestExpense
Income tax3 months2014-04-01 to 2014-06-30$302.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2014-01-01 to 2014-06-30$620.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2014-04-01 to 2014-06-30$344.0mus-gaap:NetIncomeLoss
Net income6 months2014-01-01 to 2014-06-30$712.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2014-04-01 to 2014-06-30$2.19us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2014-01-01 to 2014-06-30$4.54us-gaap:EarningsPerShareDiluted
Basic EPS3 months2014-04-01 to 2014-06-30$2.22us-gaap:EarningsPerShareBasic
Basic EPS6 months2014-01-01 to 2014-06-30$4.59us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2014-04-01 to 2014-06-30157,046,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2014-01-01 to 2014-06-30156,846,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Capital expenditure6 months2014-01-01 to 2014-06-30$216.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2014-01-01 to 2014-06-30$86.0mus-gaap:PaymentsOfDividends
Share repurchases6 months2014-01-01 to 2014-06-30$152.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2014-06-30$1.59bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-06-30$14.09bnus-gaap:AssetsCurrent
Total assetsAt period end2014-06-30$23.12bnus-gaap:Assets
Current liabilitiesAt period end2014-06-30$7.88bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-06-30$13.12bnus-gaap:Liabilities
Long-term debtAt period end2014-06-30$2.60bnus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2014-06-30$10.00bnus-gaap:StockholdersEquity
Shares outstandingAt period end2014-06-30154,254,938 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001193125-14-287100. Last ingested by Listed: Nov 13, 2026, 14:11 ET. Listed shows no prices and gives no investment advice.